Bicara's Ficera Faces Execution Risk Despite Breakthrough Data Amid C-Suite Overhaul

Bicara's drug Ficera, despite showing breakthrough three-year data, faces significant execution risk in its commercialization efforts due to an ongoing overhaul of the company's C-suite leadership.